Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

NCT01059305 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Lack of primary outcome efficacy.

Conditions

Skin Cancer

Interventions

DRUG: Erlotinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]